| Catalog No. | HM824016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | MHC II |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | IMP-321,IMP321,LAG-3Ig,LAG3-Ig,hLAG-3-Ig,hLAG-3Ig,sLAG-3-Ig,CAS:1800476-36-1 |
|---|
| Background | Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
